HC Wainwright Trims Oculis (NASDAQ:OCS) Target Price to $28.00

Oculis (NASDAQ:OCS) had its target price trimmed by HC Wainwright from $29.00 to $28.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Oculis’ Q2 2024 earnings at ($0.37) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.35) EPS and FY2024 earnings at ($1.44) EPS.

A number of other equities analysts also recently weighed in on the company. Wedbush reaffirmed an outperform rating and set a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th. Robert W. Baird dropped their price objective on Oculis from $64.00 to $35.00 and set an outperform rating on the stock in a research note on Tuesday, March 19th. Finally, Chardan Capital reiterated a buy rating and set a $30.00 price objective on shares of Oculis in a research note on Tuesday, March 19th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of $29.14.

Oculis Trading Up 0.6 %

NASDAQ:OCS opened at $12.02 on Wednesday. Oculis has a twelve month low of $9.05 and a twelve month high of $14.50. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $11.85 and a two-hundred day moving average price of $11.24.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. Equities analysts predict that Oculis will post -1.72 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently made changes to their positions in OCS. abrdn plc bought a new stake in Oculis in the 4th quarter valued at $15,980,000. Compagnie Lombard Odier SCmA raised its stake in Oculis by 47.3% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after acquiring an additional 30,750 shares during the period. Searle & CO. bought a new stake in Oculis in the 4th quarter valued at $112,000. Wolverine Asset Management LLC bought a new stake in Oculis in the 3rd quarter valued at $77,000. Finally, Barclays PLC bought a new stake in Oculis in the 2nd quarter valued at $44,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.